Menstrual migraine affects up to 25% of female migraineurs in the general population and 22%-70% of patients who present to headache clinics. In women diagnosed with menstrual migraine, perimenstrual migraines are associated with considerably greater disability than their non-menstrual attacks. Patients with chronic migraine who are receiving preventive therapy and experiencing breakthrough menstrual migraine headaches may benefit from perimenstrual elevation of the dose of the preventive medication.
Short-term, perimenstrual use of preventive agents (eg, frovatriptan) can be beneficial for patients with chronic and severe menstrual migraine. In patients who do not respond to standard preventive measures, hormonal therapy may be beneficial. Options include estrogen supplementation with a transdermal patch or oral contraceptives.
Learn more about migraine variants.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Jasvinder P. Chawla. Fast Five Quiz: Treatment of Chronic Migraine - Medscape - Mar 07, 2022.